Merck & Co., Inc. (LON:MRK)

Market Cap	196.56B
Revenue (ttm)	47.79B
Net Income (ttm)	14.16B
Shares Out	n/a
EPS (ttm)	5.62
PE Ratio	13.88
Forward PE	11.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,430
Average Volume	366,966
Open	45.00
Previous Close	44.50
Day's Range	44.18 - 45.00
52-Week Range	44.00 - 63.00
Beta	0.66
RSI	16.96
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Specialty Retail
• Sector: Consumer Discretionary
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD